Document is current
Any future updates will be listed below
-
Authors
Wagner, Sandra https://orcid.org/0000-0002-3251-3754
Girerd, Nicolas
Lemonnier, Claire
Yena, Kofivi https://orcid.org/0009-0001-7972-1147
Lamiral, Zohra
Duarte, Kevin
Merkling, Thomas
Merckle, Ludovic
Bozec, Erwan
Dougkas, Anestis
Hoge, Axelle
Guillaume, Michèle
Rossignol, Patrick
Nazare, Julie-Anne
Vors, Cécile
Boivin, Jean-Marc
Michalski, Marie-Caroline https://orcid.org/0000-0002-2956-901X
-
Funding
Funding for this research was provided by:
Fondation pour la Recherche Médicale (Equipe FRM EQU202103012668)
Centre Hospitalier universitaire de nancy (Centre Hospitalier universitaire de nancy)
Programme Hospitalier de Recherche Clinique Inter‐régional 2013 (Programme Hospitalier de Recherche Clinique Inter‐régional 2013)
Contrat de Plan Etat‐ Lorraine (Contrat de Plan Etat‐ Lorraine)
“Fonds Européen de Développement Régional” (“Fonds Européen de Développement Régional” (FEDER Lorraine))
ANR investissement d'avenir (ANR‐15‐RHU‐0004)
Agence Nationale de la Recherche (ANR‐15‐IDEX‐04‐LUE, ANR-15-CE14-0032-01, ANR-16-ECVD-0002-02))
the sixth European Union—Framework Program (EU-FP) Network of Excellence Ingenious HyperCare (LSHM-CT-2006–037093)
the seventh EU-FP (#261409)
7th Framework Program grant (#305507)
Seventh Framework Programme (FP7#602904)
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 1 July 2025
First Online: 30 August 2025
Declarations
:
: M.-C. M. received research funding from CNIEL, Sodiaal-Candia R&I, and Danone Nutricia Research, congress travel funding from CNIEL and symposium honorarium from IMGC, which are not related to the present epidemiological study. PR received grants and personal fees from Vifor Fresenius Medical Care Renal Pharma, personal fees from Idorsia, personal fees from KBP, Sanofi, NovoNordisk, personal fees from Ablative Solutions, non-financial support from G3P, personal fees from Corvidia, grants, personal fees from Relypsa, a Vifor company, and Vifor, personal fees from CardioRenal, grants and personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from CVRx, personal fees from Fresenius, grants and personal fees from Novartis, personal fees from Grunenthal, personal fees from Servier, personal fees from Stealth Peptides, all outside the submitted work. NG received honoraria from AstraZeneca, Bayer, Boehringer, Echosens, Lilly, Roche diagnostics, Novartis. PR: reports consulting for Idorsia, G3P, honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, Cincor, CVRx, Fresenius, KBP biosciences, Novartis, NovoNordisk, Relypsa, Servier, and Vifor Fresenius Medical Care Renal Pharma; and travel grants from AstraZeneca, Bayer, CVRx, Novartis, and Vifor Fresenius Medical Care Renal Pharma; Cofounder: CardioRenal, all outside the submitted work. The other co-authors have no conflicts of interest to disclose related to the submitted work, and declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The research protocols were all approved by the local Ethics Committee (Comité de Protection des Personnes Est III— Nancy—France), and all study participants gave informed written consent. The informed written consent was previously approved by the local Ethics Committee.
